Skip to content

Author

S. B. van Waalwijk van Doorn-Khosrovani

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Mapping off-label use and reimbursement pathways for oncology drugs in The Netherlands: a cross-sectional observational study.

BACKGROUND Off-label use of anticancer medicines is common. Investigator-initiated trials evaluating off-label indications often do not result in label expansion. Additionally, off-label use is often considered when approved treatments are lacking or exhausted. Such use may lead to uncertain efficacy and safety and pos...

H. Timmer, A. Huisman, H. Gelderblom et al. · 0 citations
Sep 2026

Critical appraisal of combination therapies: the impact of trial design on Benefit-Risk outcomes.

Combination therapies are widely used in oncology due to their potential to improve therapeutic efficacy and overcome drug resistance. However, these potential advantages must be weighed against added toxicity, treatment burden, and costs. In this commentary, we examine some recent examples of divergent opinions by the...

F. de Jong, L. Douma, P. Baas et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.